Immutep Ltd operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Immutep Ltd with three other
companies in this sector in the United States:
sales of $1.52 million
Aytu Bioscience Inc
Starpharma Holdings Limited
of which 100%
During the year ended June of 2019, sales at
Immutep Ltd were $4.31 million.
decrease of 20.7%
versus 2018, when the company's sales were $5.44 million.
Contributing to the drop in overall sales was the 24.0% decline
in Cancer Immunotherapy, from $5.30 million to $4.03 million.
However, these declines were partially offset by the increase in sales of
Unallocated (up 242.5% to $1.32 million)